CGS 20625

Pricing Availability   Qty
Cat.No. 2467 - CGS 20625 | C18H19N3O2 | CAS No. 111205-55-1
Description: Selective benzodiazepine partial agonist
Chemical Name: 5,6,7,8,9,10-Hexahydro-2-(4-methoxyphenyl)cyclohepta[b]pyrazolo[3,4-d]pyridin-3(2H)-one
Purity: ≥99% (HPLC)
Literature (7)

Biological Activity

Selective, partial agonist for the benzodiazepine binding site of the GABAA receptor. Potently inhibits [3H]-flunitrazepam binding to central benzodiazepine receptors (IC50 = 1.3 nM) and displays weak affinity for peripheral benzodiazepine (IC50 = 0.68 - 2.25 μM) and GABA binding sites (IC50 > 10000 μM). Displays anxiolytic activity in vivo following oral administration..

Technical Data

M. Wt 309.36
Formula C18H19N3O2
Storage Store at +4°C
Purity ≥99% (HPLC)
CAS Number 111205-55-1
PubChem ID 163844
Smiles COC1=CC=C(C=C1)N1N=C2C(=CNC3=C2CCCCC3)C1=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 30.94 100
ethanol 7.73 25

Preparing Stock Solutions

The following data is based on the product molecular weight 309.36. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.23 mL 16.16 mL 32.32 mL
5 mM 0.65 mL 3.23 mL 6.46 mL
10 mM 0.32 mL 1.62 mL 3.23 mL
50 mM 0.06 mL 0.32 mL 0.65 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:


References are publications that support the biological activity of the product.

Bennett (1987) Pharmacology of the pyrazolo-type compounds: agonist, antagonist and inverse agonist actions. Physiol.Behav. 41 241 PMID: 2893398

Williams et al (1989) CGS 20625, a novel pyrazolopyridine anxiolytic. J.Pharmacol.Exp.Ther. 248 89 PMID: 2563294

Jarvis et al (1990) CGS 20625, a novel pyrazolopyridine with selective anxiolytic activity. Prog.Clin.Biol.Res. 361 477 PMID: 1981266

If you know of a relevant reference for CGS 20625, please let us know.

View Related Products by Target

View Related Products by Product Action

View all GABAA Receptor Benzodiazepines

Keywords: CGS 20625, CGS 20625 supplier, Selective, central, benzodiazepine, receptor, partial, agonists, GABAA, Receptors, CGS20625, 2467, Tocris Bioscience

Citations for CGS 20625

Citations are publications that use Tocris products.

Currently there are no citations for CGS 20625. Do you know of a great paper that uses CGS 20625 from Tocris? Please let us know.

Reviews for CGS 20625

There are currently no reviews for this product. Be the first to review CGS 20625 and earn rewards!

Have you used CGS 20625?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Ion Channel

Ion Channel Product Listing

A collection of around 500 products for ion channel research, the listing includes research tools for the study of:

  • Ligand-gated ion channels
  • Voltage-gated ion channels
  • Other Ion Channels

Pain Research Product Guide

A collection of over 280 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
GABA Receptors

GABA Receptors Scientific Review

Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.


Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.


Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.


Pain Poster

Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.


Schizophrenia Poster

Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.